Revolution Medicines, Inc. Common Stock
RVMD
$200.87
+0.50%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, with a pipeline built around RAS(ON) inhibitors designed to bind directly to RAS variants as monotherapy or in combination with other agents. The company is a differentiated platform player in the competitive RAS-targeting landscape, leveraging proprietary structure-based drug discovery capabilities to create small molecules tailored to unconventional binding sites. The investor narrative has been transformed by the rapid FDA approval of Rasonque (daraxonrasib) for pancreatic cancer, which followed a Phase 3 trial showing survival doubled versus chemotherapy, and by analyst projections of up to $11.5 billion in peak sales. This commercial breakthrough, coupled with a $2.2 billion upsized public offering in April 2026, has driven the stock up more than 5x over the past year, shifting the debate from clinical risk to execution, competitive positioning, and whether the current valuation already discounts much of the opportunity.…
RVMD
Revolution Medicines, Inc. Common Stock
$200.87
Related headlines
Investment Opinion: Should I buy RVMD Today?
We assign a Hold rating on RVMD, balancing the transformative potential of Rasonque against a valuation that already embeds heroic growth assumptions. The analyst consensus is Strong Buy with an average target of $257.47, implying +24.6% upside, but the stock's 352% one-year gain and 9.28x P/B multiple suggest much of the near-term optimism is priced in. The core thesis is that RVMD offers a unique, first-in-class RAS(ON) platform with blockbuster potential, but the risk/reward is currently skewed by execution uncertainty and a stretched valuation.
Supporting evidence for the Hold includes: (1) the P/B of 9.28x is more than double the historical average of ~3.5x and well above the 3x–6x range for clinical-stage oncology peers; (2) revenue is currently $0, with consensus forward revenue estimates ranging wildly from $3.91 billion to $14.26 billion, highlighting the lack of visibility; (3) profitability remains deeply negative, with a Q2 2026 net loss of $644.37 million and an operating cash burn of $741.48 million; and (4) the balance sheet is strong with $820.29 million in cash and a current ratio of 7.14, but the burn rate could necessitate further dilution. The implied upside to the average target is +24.6%, but the downside to the low target is -13.4%, and the stock's beta of 1.406 amplifies both directions.
The biggest risks that could invalidate the thesis are: (1) a slower-than-expected commercial launch of Rasonque, which would delay the revenue ramp and pressure the valuation; (2) competitive threats from other RAS-targeting therapies or new entrants; and (3) a macro-driven rotation out of high-multiple biotech stocks. We would upgrade to Buy if the P/B compresses below 6x or if early launch metrics show robust adoption, and we would downgrade to Sell if revenue growth fails to materialize or if the cash burn accelerates beyond current projections. Relative to its history and peers, RVMD appears overvalued, but the premium may be justified if the company delivers on its blockbuster potential.
Sign up to view all
RVMD 12-Month Price Forecast
We maintain a neutral stance on RVMD, acknowledging the transformative potential of Rasonque but recognizing that the current valuation already reflects significant optimism. The stock's 352% one-year gain and 9.28x P/B multiple leave little room for execution missteps, while the pre-revenue status and heavy cash burn add risk. The analyst consensus is strongly bullish, but the wide target dispersion and recent momentum deceleration suggest caution. We would upgrade to bullish if early launch data shows robust adoption and the valuation compresses to a more reasonable level, and we would downgrade to bearish if revenue fails to materialize or if competitive threats intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $258.84 and implied upside of +28.9% versus the current price.
Average Target
$258.84
0 analysts
Implied Upside
+28.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$179 - $320
Analyst target range
The stock is covered by 22 analysts, with a consensus recommendation of "Strong Buy" and a recommendation mean of 1.30 (where 1 is a Strong Buy and 5 is a Sell). The average price target is $257.47, which implies an upside of approximately +24.6% from the current price of $206.64. The consensus is overwhelmingly bullish, with no sell ratings and a strong skew toward buy-equivalent ratings, as evidenced by recent reiterations from firms like B of A Securities, Stifel, Needham, Guggenheim, UBS, Evercore ISI, Wedbush, Oppenheimer, RBC Capital, and Truist Securities, all maintaining positive ratings in August and September 2026. This broad-based optimism reflects confidence in the Rasonque launch and the pipeline's potential, but also raises the risk of a crowded trade if sentiment shifts.
The target price range spans from a low of $179.00 to a high of $320.00, with the low target implying a -13.4% downside and the high target implying a +54.9% upside from the current price. The wide spread of $141.00 (or 68% of the current price) signals significant uncertainty among analysts regarding the commercial trajectory, competitive dynamics, and the timing of profitability. The high target of $320.00 likely assumes rapid adoption of Rasonque, successful expansion into additional indications, and potentially a takeover premium, while the low target of $179.00 may price in slower launch, competitive threats, or dilution from future financing. The estimated EPS average of $14.32 for the forward year, with a range of $5.16 to $30.16, further illustrates the wide dispersion of earnings expectations. Given the recent FDA approval and the strong institutional support, the analyst community appears to be in a "wait and see" mode for the first commercial quarter, but the tight clustering of recent ratings around Buy suggests that any positive launch data could lead to further target upgrades.
Bulls vs Bears: RVMD Investment Factors
The bull case rests on a transformative FDA approval, a multi-billion-dollar market opportunity, and a fortress balance sheet, while the bear case centers on an extreme valuation, pre-revenue losses, and a parabolic stock move that may have already priced in much of the good news. Currently, the bear evidence appears slightly stronger on a risk-adjusted basis: the P/B of 9.28x is more than double the historical average, the company is burning over $700 million per quarter, and the stock is up 352% in a year, making it vulnerable to any negative catalyst. The single most important tension is whether Rasonque's commercial launch can ramp fast enough to justify the current valuation—if early sales data disappoint, the stock could face a severe multiple compression, but if adoption exceeds expectations, the bull case could quickly reassert itself. The analyst consensus remains overwhelmingly bullish, but the wide target range and recent momentum deceleration suggest caution is warranted.
Bullish
- FDA Approval De-Risks Lead Asset: Rasonque (daraxonrasib) received FDA approval for pancreatic cancer following a Phase 3 trial that doubled survival versus chemotherapy. This regulatory milestone transforms RVMD from a clinical-stage story to a commercial-stage company with a first-in-class RAS(ON) inhibitor.
- Massive Addressable Market Opportunity: Analysts project peak sales of up to $11.5 billion for Rasonque, with consensus revenue estimates for the forward year averaging $7.70 billion (range $3.91B–$14.26B). This reflects a multi-billion-dollar commercial opportunity in RAS-addicted cancers, a historically undruggable target.
- Strong Analyst Consensus and Upside: 22 analysts cover RVMD with a consensus rating of 'Strong Buy' (mean 1.30) and an average price target of $257.47, implying +24.6% upside from the current price of $206.64. The high target of $320.00 suggests +54.9% potential.
- Robust Balance Sheet Supports Launch: The company raised $2.2 billion in an upsized public offering in April 2026, ending Q2 2026 with $820.29 million in cash and a current ratio of 7.14. Debt-to-equity is just 0.097, providing ample liquidity to fund commercialization without immediate financing pressure.
Bearish
- Extreme Valuation Leaves No Room for Error: The price-to-book ratio of 9.28x is well above the historical average of ~3.5x and the clinical-stage oncology peer range of 3x–6x. This premium pricing assumes flawless commercial execution and blockbuster status, making the stock vulnerable to any disappointment.
- Pre-Revenue with Widening Losses: Q2 2026 revenue was $0, with a net loss of $644.37 million (EPS -$3.06), significantly wider than the -$247.79 million loss in Q2 2025. R&D expenses surged to $394.92 million, and operating cash burn was $741.48 million in the quarter, highlighting the capital intensity of the launch phase.
- Parabolic Price Move Signals Overextension: The stock is up 352.17% over the past year and 161.50% year-to-date, vastly outperforming the S&P 500's +15.01% and +12.86%. Such a steep ascent often precedes mean-reversion, and the 1-month change of -1.24% suggests momentum is already fading.
- High Volatility and Drawdown Risk: With a beta of 1.406, RVMD is ~41% more volatile than the market. The maximum drawdown over the past year was -24.95%, and the stock trades at 90.3% of its 52-week range, leaving little cushion if sentiment reverses.
RVMD Technical Analysis
RVMD is in a powerful, sustained uptrend, with a 1-year price change of +352.17% and a year-to-date gain of +161.50%, massively outperforming the S&P 500's +15.01% and +12.86% over the same periods. At a current price of $206.64, the stock is trading at approximately 90.3% of its 52-week range (low of $45.72, high of $224.31), positioning it near the upper end of its annual range. This proximity to highs signals strong momentum but also raises the risk of overextension, especially after such a parabolic move, and suggests that any negative catalyst could trigger a sharp mean-reversion pullback. The stock's beta of 1.406 indicates it is roughly 41% more volatile than the broader market, which amplifies both upside and downside moves and warrants careful position sizing.
Short-term momentum has decelerated markedly, with a 1-month price change of -1.24% and a 3-month gain of +9.19%, a sharp contrast to the explosive 6-month gain of +108.47%. The 1-month relative strength versus SPY is -1.83%, indicating underperformance during the past month, while the 3-month relative strength is +5.85%, showing that the stock has only modestly outpaced the market recently. This divergence between the massive 1-year trend and the recent flat-to-negative 1-month performance suggests the stock is digesting its enormous gains, potentially forming a consolidation pattern. The current price of $206.64 is slightly above the previous close of $205.89, with a daily change of +0.36%, and volume of 1,570,264 shares, which is relatively light and may indicate waning near-term conviction.
Key technical levels are defined by the 52-week high of $224.31 as immediate resistance and the 52-week low of $45.72 as distant support, though intermediate support likely lies near the $180-$190 area where the stock consolidated in July 2026. A breakout above $224.31 would signal a resumption of the primary uptrend and could open the door to new all-time highs, while a breakdown below $190 could trigger a deeper correction toward the $160-$170 zone. The maximum drawdown of -24.95% over the past year highlights the stock's capacity for sharp reversals, and with a beta of 1.406, investors should expect amplified moves relative to the market. The short ratio of 5.53 suggests that short sellers have not yet capitulated, which could fuel further upside if positive catalysts emerge and force covering.
Beta
1.40
1.40x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$46-$224
Price range past year
Annual Return
+331.3%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | +0.9% |
| 3m | +5.1% | +3.4% |
| 6m | +108.3% | +14.4% |
| 1y | +331.3% | +16.2% |
| ytd | +154.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is a pre-revenue clinical-stage biotechnology company, with reported revenue of $0 for the most recent quarter (Q2 2026) and $0 for each of the trailing four quarters, though a small collaboration revenue line of $7.014 million appears in the segment data. The company's revenue trajectory is essentially non-existent as it transitions from clinical development to commercialization following the FDA approval of Rasonque, and the first meaningful product revenue is expected to commence in late 2026 or 2027. The analyst consensus estimated revenue average of $7.70 billion reflects an extraordinary ramp expectation, with a low estimate of $3.91 billion and a high estimate of $14.26 billion, underscoring the wide range of outcomes and the binary nature of the investment case. This growth trajectory, while potentially explosive, is entirely dependent on successful launch execution and market penetration in pancreatic cancer and eventually other RAS-driven tumors.
Profitability remains deeply negative, with a net loss of $644.37 million in Q2 2026, or -$3.06 per diluted share, and an EBITDA loss of $620.59 million for the same period. Gross margin is not meaningful at 0% due to the absence of product revenue, and operating expenses are substantial, with research and development costs of $394.92 million and general and administrative expenses of $110.21 million in Q2 2026. The net loss has widened significantly from -$247.79 million in Q2 2025 to -$644.37 million in Q2 2026, driven by increased R&D spending and a $139.24 million negative swing in other income/expenses. The company's path to profitability is contingent on successful commercialization, and the current burn rate of approximately $741.48 million in operating cash flow for Q2 2026 alone highlights the capital intensity of the launch phase.
The balance sheet remains robust despite the heavy cash burn, with a current ratio of 7.14 and a debt-to-equity ratio of just 0.097, indicating minimal leverage and ample liquidity. Free cash flow for the trailing twelve months stands at -$1.59 billion, reflecting the company's significant investment in its pipeline and commercial infrastructure, but the $2.2 billion capital raise in April 2026 has bolstered the cash position to $820.29 million as of Q2 2026. The return on equity is deeply negative at -69.35%, and return on assets is -30.12%, which is typical for a pre-commercial biotech but underscores the lack of current profitability. The company's cash per share of $18.67 and quick ratio of 11.38 provide a strong liquidity cushion, but the ongoing cash burn means that additional financing may be required if product revenues do not materialize as quickly as anticipated.
Quarterly Revenue
$0.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.6B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Because Revolution Medicines has negative net income (trailing twelve-month EPS of -$0.07 and net loss of $644.37 million in Q2 2026), the PE ratio is not meaningful, and the PS ratio is also not applicable due to the absence of revenue. Therefore, the most appropriate valuation metric is the price-to-book (P/B) ratio, which currently stands at 9.28x, reflecting the market's premium on the company's intellectual property and pipeline rather than current earnings. The forward PE of -34.57 and trailing PE of -13.39 are negative and thus not useful for valuation, while the EV/EBITDA of -13.68 further confirms the lack of positive cash flow. The gap between the current P/B of 9.28x and the historical average P/B of approximately 3.5x over the past two years implies that the market is pricing in a dramatic transformation to profitability and blockbuster commercial success.
Comparing to the biotechnology industry, where the average P/B for clinical-stage oncology companies typically ranges from 3x to 6x, RVMD's P/B of 9.28x represents a premium of roughly 55% to 200% over peers. This premium is justified by the company's first-in-class RAS(ON) inhibitor platform, the recent FDA approval of Rasonque, and the potential for $11.5 billion in peak sales, which is well above the average peak sales estimate for a single oncology asset. However, the premium also reflects the high expectations embedded in the stock price, and any delay or disappointment in the commercial launch could lead to a sharp multiple compression. The price-to-free-cash-flow ratio of -52.99 is negative and not comparable, but the enterprise value multiple of -63.36 highlights the significant cash burn relative to enterprise value.
Historically, RVMD's P/B ratio has ranged from a low of 2.16x in Q1 2023 to a high of 15.15x in Q2 2026, with the current 9.28x sitting in the upper quartile of that range. The stock's P/B has expanded dramatically from 3.20x in Q1 2025 to 9.28x in Q2 2026, a nearly threefold increase, driven by the surge in share price and the capital raise that increased book value. This historical context suggests that the market is currently pricing in optimistic expectations, and while the P/B is below the recent peak of 15.15x, it remains well above the long-term average. Investors should consider whether the current valuation adequately reflects the risks of commercialization, competition, and potential dilution, or whether it leaves little room for error.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial for RVMD. The company is pre-revenue, with Q2 2026 revenue of $0 and a net loss of $644.37 million, up from a $247.79 million loss in Q2 2025. Operating cash burn reached $741.48 million in the quarter, and free cash flow over the trailing twelve months was -$1.59 billion. While the $2.2 billion capital raise in April 2026 bolstered cash to $820.29 million, the current burn rate implies that additional financing may be needed if product revenues do not materialize as quickly as anticipated, potentially leading to further dilution. The company's entire near-term outlook depends on the successful launch of a single asset, Rasonque, creating significant concentration risk.
Market and competitive risks are equally pressing. RVMD trades at a price-to-book ratio of 9.28x, a premium of roughly 55% to 200% over the typical 3x–6x range for clinical-stage oncology peers, and well above its own historical average of ~3.5x. This valuation leaves little room for error; any delay in the launch, competitive threat from other RAS-targeting therapies, or macro-driven rotation out of high-multiple biotech could trigger a sharp correction. The stock's beta of 1.406 means it is ~41% more volatile than the broader market, amplifying downside moves. Recent news highlights the stock's 5x surge and questions whether the upside is already priced in, while the $2.2 billion raise, though de-risking, came with immediate dilution.
The worst-case scenario would involve a combination of slower-than-expected Rasonque adoption, competitive encroachment, and a financing crunch. If the launch disappoints and the company needs to raise capital at a lower valuation, the stock could retest its 52-week low of $45.72, representing a -77.9% decline from the current price of $206.64. Even a less severe scenario, such as a pullback to the analyst low target of $179.00, would imply a -13.4% loss. Given the maximum drawdown of -24.95% over the past year, investors should be prepared for significant volatility, and a realistic bear case could see the stock fall 30–50% from current levels if execution falters.
FAQ
The key risks for RVMD are ranked as follows: (1) Execution risk on the Rasonque launch—if adoption is slower than expected, revenue estimates could be cut, and the stock could fall toward the analyst low target of $179 (-13.4%) or lower; (2) Financial risk from heavy cash burn—Q2 2026 operating cash flow was -$741.48 million, and while the company has $820.29 million in cash, additional financing may be needed, potentially diluting shareholders; (3) Competitive risk—other companies are developing RAS-targeting therapies, and a superior competitor could erode Rasonque's market share; (4) Valuation risk—the P/B of 9.28x is well above historical and peer averages, making the stock vulnerable to a sharp correction if growth expectations are not met. The high beta of 1.406 amplifies these risks.
Our 12-month forecast for RVMD includes three scenarios: a bull case (25% probability) with a target range of $280–$320, driven by better-than-expected Rasonque sales and pipeline expansion; a base case (55% probability) with a target range of $240–$270, assuming a solid launch and revenue ramp in line with consensus; and a bear case (20% probability) with a target range of $160–$180, reflecting launch disappointments or competitive threats. The base case is most likely, anchored by the analyst average target of $257.47 and consensus revenue estimates of $7.70 billion. The key assumption is that Rasonque gains traction in pancreatic cancer without major safety or reimbursement issues. However, the wide range of outcomes means investors should be prepared for volatility.
RVMD appears overvalued on traditional metrics, with a price-to-book ratio of 9.28x compared to its historical average of ~3.5x and the 3x–6x range for clinical-stage oncology peers. The company has no revenue and negative earnings, so PE and PS ratios are not meaningful, but the EV/EBITDA of -13.68 and price-to-free-cash-flow of -52.99 highlight the lack of positive cash flow. The market is pricing in a dramatic transformation to profitability, with consensus revenue estimates for the forward year averaging $7.70 billion, but the wide range ($3.91B–$14.26B) underscores the uncertainty. While the premium may be justified by the potential of Rasonque (peak sales estimates up to $11.5 billion), the current valuation leaves little room for error, and any disappointment could lead to significant multiple compression.
RVMD presents a high-risk, high-reward opportunity that may be suitable for aggressive investors, but it is not a conservative buy at current levels. The stock trades at $206.64, with a P/B of 9.28x, well above its historical average and peer group, reflecting high expectations for its newly approved pancreatic cancer drug, Rasonque. Analysts have a Strong Buy consensus with an average target of $257.47, implying +24.6% upside, but the low target of $179 suggests -13.4% downside. The company is pre-revenue with a Q2 2026 net loss of $644.37 million and an operating cash burn of $741.48 million, so execution risk is significant. For investors willing to accept volatility (beta 1.406) and a long-term horizon, RVMD could be a good buy on pullbacks, but chasing the stock after a 352% one-year gain carries substantial risk.
RVMD is better suited for long-term investors who can tolerate significant volatility and have a time horizon of at least 3–5 years. The company is in the early stages of commercializing its first product, and the full revenue ramp and path to profitability will take several years to unfold. The stock's beta of 1.406 and maximum drawdown of -24.95% over the past year indicate high short-term risk, making it less appropriate for short-term trading unless one is actively managing positions around catalysts. The lack of dividends and negative earnings mean there is no income component. A minimum holding period of 2–3 years is suggested to allow for the commercial launch to mature and for potential pipeline readouts to add value.